Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
Open Access
- 4 August 2023
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 194, 113278
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
- F. Hoffmann-La Roche Ltd
This publication has 62 references indexed in Scilit:
- Twenty‐five years of confirmatory adaptive designs: opportunities and pitfallsStatistics in Medicine, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trialTrials, 2012
- Cancers of unknown primary origin: current perspectives and future therapeutic strategiesJournal of Translational Medicine, 2012
- The Danish Cancer RegistryScandinavian Journal of Public Health, 2011
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 2009
- Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timelinessEuropean Journal of Cancer, 2009
- STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled TrialClinical Oncology, 2008
- Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine KinasesClinical Cancer Research, 2008
- The Finnish Cancer Registry as Follow-Up Source of a Large Trial CohortActa Oncologica, 2002